Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel, Franck; Colombel, Jean Frederic; Filippi, Jeromeet al.
[en] BACKGROUND & AIMS: Parenteral methotrexate is an effective treatment for patients with Crohn's disease, but has never been adequately evaluated in patients with ulcerative colitis (UC). We conducted a randomized controlled trial to determine its safety and efficacy in patients with steroid-dependent UC. METHODS: We performed a double-blind, placebo-controlled trial to evaluate the efficacy of parenteral methotrexate (25 mg/wk) in 111 patients with corticosteroid-dependent UC at 26 medical centers in Europe from 2007 through 2013. Patients were given prednisone (10 to 40 mg/d) when the study began and were randomly assigned to groups (1:1) given placebo or methotrexate (intramuscularly or subcutaneously, 25 mg weekly) for 24 weeks. The primary end point was steroid-free remission (defined as a Mayo score </=2 with no item >1 and complete withdrawal of steroids) at week 16. Secondary endpoints included clinical remission (defined as a Mayo clinical subscore </=2 with no item >1) and endoscopic healing without steroids at weeks 16 and/or 24, remission without steroids at week 24, and remission at both weeks 16 and 24. RESULTS: Steroid-free remission at week 16 was achieved by 19 of 60 patients given methotrexate (31.7%) and 10 of 51 patients given placebo (19.6%)--a difference of 12.1% (95% confidence interval [CI]: -4.0% to 28.1%; P = .15). The proportion of patients in steroid-free clinical remission at week 16 was 41.7% in the methotrexate group and 23.5% in the placebo group, for a difference of 18.1% (95% CI: 1.1% to 35.2%; P = .04). The proportions of patients with steroid-free endoscopic healing at week 16 were 35% in the methotrexate group and 25.5% in the placebo group--a difference of 9.5% (95% CI: -7.5% to 26.5%; P = .28). No differences were observed in other secondary end points. More patients receiving placebo discontinued the study because of adverse events (47.1%), mostly caused by UC, than patients receiving methotrexate (26.7%; P = .03). A higher proportion of patients in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .006). CONCLUSIONS: In a randomized controlled trial, parenteral methotrexate was not superior to placebo for induction of steroid-free remission in patients with UC. However, methotrexate induced clinical remission without steroids in a significantly larger percentage of patients, resulting in fewer withdrawals from therapy due to active UC. ClinicalTrials.gov ID NCT00498589.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Carbonnel, Franck
Colombel, Jean Frederic
Filippi, Jerome
Katsanos, Konstantinos H.
Peyrin-Biroulet, Laurent
Allez, Mathieu
Nachury, Maria
Novacek, Gottfried
Danese, Silvio
Abitbol, Vered
Bossa, Fabrizio
Moreau, Jacques
Bommelaer, Gilles
Bourreille, Arnaud
Fumery, Mathurin
Roblin, Xavier
Reinisch, Walter
Bouhnik, Yoram
Brixi, Hedia
Seksik, Philippe
Malamut, Georgia
Farkkila, Martti
Coulibaly, Baya
Dewit, Olivier
Louis, Edouard ; Université de Liège > Département des sciences cliniques > Hépato-gastroentérologie
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
A. Timmer, J.W. McDonald, D.J. Tsoulis, and et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev 9 2012 Sep 12 CD000478
M. Toruner, E.V. Loftus Jr., W.S. Harmsen, and et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease Gastroenterology 134 2008 929 936
L. Beaugerie, N. Brousse, A.M. Bouvier, and et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Lancet 374 9701 2009 1617 1625
P. Rutgeerts, W.J. Sandborn, B.G. Feagan, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
R. Panaccione, S. Ghosh, S. Middleton, and et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis Gastroenterology 146 2014 392 400
N. Nyboe Andersen, B. Pasternak, N. Friis-Møller, and et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study BMJ 350 2015 Jun 5 h2809
B.G. Feagan, P. Rutgeerts, B.E. Sands, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
M.E. van der Valk, M.J. Mangen, M. Leenders, and et al. COIN study group and the Dutch Initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study Gut 63 2014 72 79
B.G. Feagan, J. Rochon, R.N. Fedorak, and et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 299
B.G. Feagan, R.N. Fedorak, E.J. Irvine, and et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
R. Oren, N. Arbert, S. Odes, and et al. Methotrexate in chronic active ulcerative colitis: a double blind randomized Israeli multicenter trial Gastroenterology 110 1996 1416 1421
N. Chande, Y. Wang, J.K. MacDonald, and et al. Methotrexate for induction of remission in ulcerative colitis Cochrane Database Syst Rev 8 2014 CD006618
E.F. Stange, S.P. Travis, S. Vermeire, and et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis J Crohns Colitis 2 2008 1 23
P.J. Brooks, W.J. Spruill, R.C. Parish, and et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis Arthritis Rheum 33 1990 91 94
J.W. Jundt, B.A. Browne, G.P. Fiocco, and et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing J Rheumatol 20 1993 1845 1849
H.H. Herfarth, M.T. Osterman, K.L. Isaacs, and et al. Efficacy of methotrexate in ulcerative colitis: failure or promise Inflamm Bowel Dis 16 2010 1421 1430
S. Ardizzone, G. Maconi, A. Russo, and et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis Gut 55 2006 47 53
A. Wilson, V. Patel, N. Chande, and et al. Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease Aliment Pharmacol Ther 37 2013 340 345
M.H. Schiff, J.S. Jaffe, and B. Freundlich Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration Ann Rheum Dis 73 2014 1549 1551
B.G. Feagan, W.J. Sandborn, G. D'Haens, and et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis Gastroenterology 145 2013 149 157
B. Jharap, W.J. Sandborn, W. Reinisch, and et al. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis Aliment Pharmacol Ther 42 2015 1082 1092
X. Mariette, D. Cazals-Hatem, J. Warszawki, and et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 2002 3909 3915
N. Nyboe Andersen, B. Pasternak, S. Basit, and et al. Association between tumor necrosis factor α antagonists and risk of cancer in patients with inflammatory bowel disease JAMA 311 2014 2406 2413
M.T. Osterman, W.J. Sandborn, J.-F. Colombel, and et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology 146 2014 941 949
L. Peyrin-Biroulet, K. Khosrotehrani, F. Carrat, and et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease Gastroenterology 14 2011 1621 1628
J. Maté-Jiménez, C. Hermida, J. Cantero-Perona, and et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease Eur J Gastroenterol Hepatol 12 2000 1227 1233
W.J. Sandborn, G. van Assche, W. Reinisch, and et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265
W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109
